Medicine by Design

加拿大有潜力在再生医疗技术方面引领世界，对人类健康产生深远影响。这种影响是通过医学设计成为可能-一个新的多伦多大学的倡议，是通过加拿大第一卓越研究基金的支持。 这一举措也为加拿大带来了重大的经济机遇。它将把新技术和科学战略纳入多伦多大学的再生医学项目，并发展本地制造快速实验室到患者技术的能力，使加拿大能够引领全球医疗行业的转型，成为再生医学技术的主要国际供应商。 设计医学建立在加拿大在再生医学方面的领导地位的历史基础上，该历史始于1961年多伦多大学发现干细胞。自2000年代中期以来，该大学的生物医学工程师已经取得了几项重大突破从将活细胞与合成聚合物结合到创造人造器官和组织。 该倡议由一个国际公认的科学领导人小组领导，他们可以利用多伦多大学的研究中心、基础设施和专家网络。他们将与附属医院的同事合作，如大学健康网络，患病儿童医院和山。西奈医院;在区域，国家和国际学术合作伙伴，如特德罗杰斯心脏研究中心，麦克尤恩再生医学中心，安大略癌症研究所，瑞典卡罗林斯卡研究所和英国再生医学平台;以及专注于先进制造和商业化的组织，如抗体和生物制品商业化中心，MaRS创新，以及再生医学商业化中心，该中心拥有一个商业伙伴行业联盟，由大型跨国公司、中小型企业和新兴生物技术公司组成。 “设计医学”计划将重点关注三大支柱： Cells by Design将创造出命运和功能可以控制的细胞，以确保更安全、更有效的治疗。 Tissues by Design将创造复杂的组织，用于研究，药物发现和替换人类丢失或受损的组织。 器官设计将在体外创造和修复器官，并展示如何将这些器官成功移植到人类患者体内。 细胞、组织和器官设计计划将得到基本技术平台的支持，如发现生物标志物和细胞控制电路的基因组工程;控制身体对疾病和移植细胞、器官和组织的反应的免疫工程;以及按需制造干细胞的计划。 该基金提供的支持将使多伦多大学及其合作伙伴能够从有前途的发现转向为加拿大人和世界各地的人们提供新的更好的治疗方法。

Canada has the potential to lead the world in regenerative medical technologies that can have a profound impact on human health. This kind of impact is made possible through Medicine by Design—a new University of Toronto initiative that is supported through the Canada First Research Excellence Fund. The initiative also represents a significant economic opportunity for Canada. It will incorporate new technologies and scientific strategies into the University of Toronto’s regenerative medicine programs, and develop local capacity for manufacturing rapid lab-to-patient technologies that allows Canada to lead the transformation of the global medical industry and become a major international supplier of regenerative medicine technologies. Medicine by Design builds on a history of Canadian leadership in regenerative medicine, which started with the discovery of stem cells in 1961 at the University of Toronto. Since the mid-2000s, biomedical engineers at the university have made several significant breakthroughs—from combining living cells with synthetic polymers to creating artificial organs and tissues. The initiative is headed by a team of internationally recognized scientific leaders who have access to a network of research centres, infrastructure and experts at the University of Toronto. They will collaborate with colleagues in affiliated hospitals such as the University Health Network, the Hospital for Sick Children and Mt. Sinai Hospital; at regional, national and international academic partners such as the Ted Rogers Centre for Heart Research, the McEwen Centre for Regenerative Medicine, the Ontario Institute for Cancer Research , Sweden’s Karolinska Institute, and the UK Regenerative Medicine Platform; and from organizations focused on advanced manufacturing and commercialization such as the Centre for the Commercialization of Antibodies and Biologics, MaRS Innovation, and the Centre for Commercialization of Regenerative Medicine, which has an industry consortium of commercial partners, consisting of large multinationals, small-medium enterprises and emerging biotechnology companies. The Medicine by Design initiative will focus on three pillars: Cells by Design will create cells whose fate and function can be controlled to ensure safer and more effective therapies. Tissues by Design will create complex tissues for use in research, drug-discovery and replacing lost or damaged tissue in humans. Organs by Design will create and repair organs outside the body and demonstrate how these organs can be successfully transplanted into human patients. The cell-, tissue- and organ-design initiatives will be supported by essential technology platforms, such as genomic engineering to discover biomarkers and cellular control circuits; immune engineering to control the body’s responses to disease and to transplanted cells, organs and tissues; and a program to manufacture stem cells on demand. The support provided by the Fund will allow the University of Toronto and its partners to move from promising discoveries to new and better treatments for Canadians and people around the world.